'Cashing In' On Biobank Networking: BC Platforms Aims To Globalize Its Finnish Model
Privately-held BC Platforms is one of the networked groups leading the way in clinical genomics data management. Its CEO tells Scrip how the company's foundational start in Finland 21 years ago allowed it to create a critical mass from which it is now expanding globally in the quest to better understand the pathogenic mechanism of diseases.
You may also be interested in...
BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.
Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.